Role of microRNAs and microRNA machinery in the pathogenesis of diffuse large B-cell lymphoma

Blood Cancer Journal

Volumn 3, Issue 10, 2013, Pages

  Caramuta, S ^a   Lee, L ^a   Ozata D M ^a   Akcakaya, P ^a   Georgii Hemming, P ^b   Xie, H ^a   Amini, R M ^b   Lawrie, C H ^c,d   Enblad, G ^b   Larsson, C ^a   Berglund, M ^b   Lui, W O ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Diffuse large B cell lymphoma; Gene expression; MicroRNA; TARBP2

Indexed keywords

DICER; INTERFERON REGULATORY FACTOR 4; MESSENGER RNA; MICRORNA; MICRORNA 103; MICRORNA 107; MICRORNA 140; MICRORNA 142 3P; MICRORNA 142 5P; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 150; MICRORNA 155; MICRORNA 16; MICRORNA 195; MICRORNA 21; MICRORNA 29A; MICRORNA 29B; MICRORNA 34A; MICRORNA 494; MICRORNA 497; MICRORNA 638; PROTEIN BCL 6; PROTEIN TARBP2; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER STAGING; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CLINICAL FEATURE; DISEASE FREE SURVIVAL; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; GERMINAL CENTER; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPH NODE; LYMPHOMA CELL LINE; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

EID: 84887501720     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.49     Document Type: Article

References (59)

1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
2. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
3. Berglund M, Thunberg U, Amini RM, Book M, Roos G, Erlanson M et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol 2005; 18: 1113-1120.
4. Berglund M, Enblad G, Flordal E, Lui WO, Backlin C, Thunberg U et al. Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization. Mod Pathol 2002; 15: 807-816.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
6. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004; 18: 3016-3027.
7. Chendrimada TP, Gregory RI, Kumaraswamy E, Norman J, Cooch N, Nishikura K et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436: 740-744.
8. Lee Y, Hur I, Park SY, Kim YK, Suh MR, Kim VN. The role of PACT in the RNA silencing pathway. EMBO J 2006; 25: 522-532.
9. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83-86.
10. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-15529.
11. Roehle A, Hoefig KP, Repsilber D, Thorns C, Ziepert M, Wesche KO et al. MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol 2008; 142: 732-744.
12. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833.
13. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 2007; 121: 1156-1161.
14. Lawrie CH, Chi J, Taylor S, Tramonti D, Ballabio E, Palazzo S et al. Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma. J Cell Mol Med 2009; 13: 1248-1260.
15. Di Lisio L, Sanchez-Beato M, Gomez-Lopez G, Rodriguez ME, Montes-Moreno S, Mollejo M et al. MicroRNA signatures in B-cell lymphomas. Blood Cancer J 2012; 2: e57.
16. Malumbres R, Sarosiek KA, Cubedo E, Ruiz JW, Jiang X, Gascoyne RD et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood 2009; 113: 3754-3764.
17. Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, Chinichian S et al. MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011; 17: 4125-4135.
18. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
19. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359: 2641-2650.
20. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, Calin GA et al. A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 2009; 41: 365-370.
21. Ma Z, Swede H, Cassarino D, Fleming E, Fire A, Dadras SS. Up-regulated Dicer expression in patients with cutaneous melanoma. PLoS One 2011; 6: e20494.
22. Valencak J, Schmid K, Trautinger F, Wallnofer W, Muellauer L, Soleiman A et al. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas. J Dermatol Sci 2011; 64: 185-190.
23. Caramuta S, Egyhazi S, Rodolfo M, Witten D, Hansson J, Larsson C et al. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol Aug 130: 2062-2070.
24. de Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics 2004; 20: 1453-1454.
25. Schmittgen TD, Jiang J, Liu Q, Yang L. A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res 2004; 32: e43.
26. Ozata DM, Caramuta S, Velazquez-Fernandez D, Akcakaya P, Xie H, Hoog A et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011; 18: 643-655.
27. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
28. Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007; 109: 4944-4951.
29. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007; 67: 6031-6043.
30. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-675.
31. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA 2007; 104: 7080-7085.
32. Ghisi M, Corradin A, Basso K, Frasson C, Serafin V, Mukherjee S et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood 2011; 117: 7053-7062.
33. Bezman NA, Chakraborty T, Bender T, Lanier LL. miR-150 regulates the development of NK and iNKT cells. J Exp Med 2011; 208: 2717-2731.
34. Lawrie CH, Saunders NJ, Soneji S, Palazzo S, Dunlop HM, Cooper CD et al. MicroRNA expression in lymphocyte development and malignancy. Leukemia 2008; 22: 1440-1446.
35. Watanabe A, Tagawa H, Yamashita J, Teshima K, Nara M, Iwamoto K et al. The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia 2011; 25: 1324-1334.
36. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
37. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T, Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007; 98: 1914-1920.
38. Sasaki N, Kuroda J, Nagoshi H, Yamamoto M, Kobayashi S, Tsutsumi Y et al. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp Hematol 2011; 39: 817-828 e811.
39. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W et al. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010; 115: 2630-2639.
40. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 2011; 17: 1722-1730.
41. Caramuta S, Lee L, Ozata DM, Akcakaya P, Xie H, Hoog A et al. Clinical and functional impact of TARBP2 over-expression in adrenocortical carcinoma. Endocr Relat Cancer 2013; 20: 551-564.
42. Thompson RC, Herscovitch M, Zhao I, Ford TJ, Gilmore TD. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/ PU.1 pathway. J Biol Chem 2011; 286: 1675-1682.
43. Dagan LN, Jiang X, Bhatt S, Cubedo E, Rajewsky K, Lossos IS. miR-155 regulates HGAL expression and increases lymphoma cell motility. Blood 2012; 119: 513-520.
44. Kerckaert JP, Deweindt C, Tilly H, Quief S, Lecocq G, Bastard C. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat Genet 1993; 5: 66-70.
45. Migliazza A, Martinotti S, Chen W, Fusco C, Ye BH, Knowles DM et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci USA 1995; 92: 12520-12524.
46. Yu D, Rao S, Tsai LM, Lee SK, He Y, Sutcliffe EL et al. The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. Immunity 2009; 31: 457-468.
47. Arribas AJ, Campos-Martin Y, Gomez-Abad C, Algara P, Sanchez-Beato M, Rodriguez-Pinilla MS et al. Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets. Blood 2012; 119: e9-e21.
48. Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 2009; 25: 13-20.
49. Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood 2009; 113: 4391-4402.
50. Chang SS, Jiang WW, Smith I, Poeta LM, Begum S, Glazer C et al. MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 2008; 123: 2791-2797.
51. Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F, Popescu I et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 2011; 54: 2089-2098.
52. Kim WK, Park M, Kim YK, Tae YK, Yang HK, Lee JM et al. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res 2011; 17: 7584-7594.
53. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol 2012; 188: 5500-5510.
54. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112: 4202-4212.
55. Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 2006; 169: 1812-1820.
56. Sugito N, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H et al. RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res 2006; 12: 7322-7328.
57. Melo S, Villanueva A, Moutinho C, Davalos V, Spizzo R, Ivan C et al. Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNAbinding protein 2-mediated microRNA processing. Proc Natl Acad Sci USA 2011; 108: 4394-4399.
58. Benkirane M, Neuveut C, Chun RF, Smith SM, Samuel CE, Gatignol A et al. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J 1997; 16: 611-624.
59. Lee JY, Kim H, Ryu CH, Kim JY, Choi BH, Lim Y et al. Merlin, a tumor suppressor, interacts with transactivation-responsive RNA-binding protein and inhibits its oncogenic activity. J Biol Chem 2004; 279: 30265-30273.